Zobrazeno 1 - 10
of 390
pro vyhledávání: '"Jenner MW"'
Autor:
Kaiser MF; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom.; Department of Haematology, The Royal Marsden Hospital, London, United Kingdom., Hall A; Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom., Walker K; Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom., Sherborne A; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom., De Tute RM; Haematological Malignancy Diagnostic Service, Leeds Cancer Centre, Leeds Teaching Hospitals Trust, Leeds, United Kingdom., Newnham N; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom., Roberts S; Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom., Ingleson E; Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom., Bowles K; Department of Haematology, Norfolk and Norwich University Hospitals NHS Trust, Norwich, United Kingdom., Garg M; Department of Haematology, Leicester Royal Infirmary, Leicester, United Kingdom., Lokare A; Department of Haematology, Birmingham Heartlands, Birmingham, United Kingdom., Messiou C; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom.; Department of Haematology, The Royal Marsden Hospital, London, United Kingdom., Houlston RS; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom., Jackson G; Department of Haematology, Newcastle University, Newcastle, United Kingdom., Cook G; Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom.; Leeds Cancer Centre, Leeds Teaching Hospitals Trust, Leeds, United Kingdom., Pratt G; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom., Owen RG; Haematological Malignancy Diagnostic Service, Leeds Cancer Centre, Leeds Teaching Hospitals Trust, Leeds, United Kingdom., Drayson MT; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom., Brown SR; Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom., Jenner MW; Department of Haematology, University Hospital Southampton, Southampton, United Kingdom.
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2023 Aug 10; Vol. 41 (23), pp. 3945-3955. Date of Electronic Publication: 2023 Jun 14.
Autor:
Jones JR; Brighton and Sussex Medical School, Brighton, UK.; Kings College Hospital, London, UK.; East Sussex NHS Trust, UK., Cairns DA; Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK., Menzies T; Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK., Pawlyn C; The Institute of Cancer Research, London, UK.; The Royal Marsden Hospital, London, UK., Davies FE; Perlmutter Cancer Center, NY Langone Health, New York, USA., Sigsworth R; Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK., Brioli A; Clinic of Internal Medicine C, Greifswald University Medicine, Greifswald, Germany., Jenner MW; University Hospital Southampton NHS Foundation Trust, Southampton, UK., Kaiser MF; The Institute of Cancer Research, London, UK.; The Royal Marsden Hospital, London, UK., Olivier C; Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK., Reed M; Brighton and Sussex Medical School, Brighton, UK., Drayson MT; Clinical Immunology, University of Birmingham, Birmingham, UK., Owen RG; St James's University Hospital, Leeds, UK., Boyd KD; The Royal Marsden Hospital, London, UK., Cook G; Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.; Clinical Immunology, University of Birmingham, Birmingham, UK., Morgan GJ; Perlmutter Cancer Center, NY Langone Health, New York, USA., Jackson GH; Department of Haematology, Newcastle University, Newcastle, UK.
Publikováno v:
EClinicalMedicine [EClinicalMedicine] 2023 Jul 27; Vol. 62, pp. 102099. Date of Electronic Publication: 2023 Jul 27 (Print Publication: 2023).
Autor:
Faustini SE; Clinical Immunology Service, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK., Hall A; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK., Brown S; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK., Roberts S; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK., Hill H; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK., Stamataki Z; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK., Jenner MW; Department of Haematology, University Hospital Southampton NHS Foundation Trust, Southampton, UK., Owen RG; The Leeds Teaching Hospitals NHS Trust, Leeds, UK., Pratt G; University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK., Cook G; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.; The Leeds Teaching Hospitals NHS Trust, Leeds, UK., Richter A; Clinical Immunology Service, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK., Drayson MT; Clinical Immunology Service, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK., Kaiser MF; The Royal Marsden Hospital NHS Foundation Trust, London, UK.; The Institute of Cancer Research, London, UK., Heaney JLJ; Clinical Immunology Service, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
Publikováno v:
British journal of haematology [Br J Haematol] 2023 Jun; Vol. 201 (5), pp. 845-850. Date of Electronic Publication: 2023 Mar 09.
Autor:
Jenner MW; University Hospital Southampton NHS Foundation Trust, Southampton, UK., Pawlyn C; The Institute of Cancer Research, London, UK.; The Royal Marsden NHS Foundation Trust, London, UK., Davies FE; Perlmutter Cancer Center, NYU Langone Health, New York, USA., Menzies T; Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK., Hockaday A; Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK., Olivier C; Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK., Jones JR; Eastbourne District General Hospital, Eastbourne, UK.; Brighton and Sussex Medical School, University of Sussex, Sussex, UK.; Kings College Hospital NHS Foundation Trust, London, UK., Karunanithi K; University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, UK., Lindsay J; East Kent Hospitals University NHS Foundation Trust, Canterbury, UK., Kishore B; University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK., Cook G; Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.; Leeds Cancer Centre, Leeds Teaching Hospitals Trust, Leeds, UK., Drayson MT; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK., Kaiser MF; The Institute of Cancer Research, London, UK.; The Royal Marsden NHS Foundation Trust, London, UK., Owen RG; Haematological Malignancy Diagnostic Service (HMDS), Leeds Cancer Centre, Leeds Teaching Hospitals Trust, Leeds, UK., Gregory W; Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK., Cairns DA; Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK., Morgan GJ; Perlmutter Cancer Center, NYU Langone Health, New York, USA., Jackson GH; Department of Haematology, Newcastle University, Newcastle, UK.
Publikováno v:
British journal of haematology [Br J Haematol] 2023 Apr; Vol. 201 (2), pp. 267-279. Date of Electronic Publication: 2022 Dec 21.
Autor:
de Tute RM; Haematological Malignancy Diagnostic Service, Leeds Cancer Centre, Leeds Teaching Hospitals Trust, Leeds, United Kingdom., Pawlyn C; The Institute of Cancer Research, London, United Kingdom.; The Royal Marsden NHS Foundation Trust, London, United Kingdom., Cairns DA; Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom., Davies FE; Perlmutter Cancer Center, NYU Langone Health, New York, NY., Menzies T; Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom., Rawstron A; Haematological Malignancy Diagnostic Service, Leeds Cancer Centre, Leeds Teaching Hospitals Trust, Leeds, United Kingdom., Jones JR; Eastbourne District General Hospital, Eastbourne, United Kingdom.; Brighton and Sussex Medical School, University of Sussex, Sussex, United Kingdom.; Kings College Hospital, NHS Foundation Trust, London, United Kingdom., Hockaday A; Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom., Henderson R; Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom., Cook G; Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom.; Kings College Hospital, NHS Foundation Trust, London, United Kingdom., Drayson MT; Leeds Cancer Centre, Leeds Teaching Hospitals Trust, Leeds, United Kingdom., Jenner MW; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom., Kaiser MF; The Institute of Cancer Research, London, United Kingdom.; The Royal Marsden NHS Foundation Trust, London, United Kingdom., Gregory WM; Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom., Morgan GJ; Perlmutter Cancer Center, NYU Langone Health, New York, NY., Jackson GH; University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom., Owen RG; Haematological Malignancy Diagnostic Service, Leeds Cancer Centre, Leeds Teaching Hospitals Trust, Leeds, United Kingdom.
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2022 Sep 01; Vol. 40 (25), pp. 2889-2900. Date of Electronic Publication: 2022 Apr 04.
Autor:
Croft J; Division of Molecular Pathology, The Institute of Cancer Research, London, UK., Ellis S; Division of Molecular Pathology, The Institute of Cancer Research, London, UK., Sherborne AL; Division of Molecular Pathology, The Institute of Cancer Research, London, UK., Sharp K; Division of Molecular Pathology, The Institute of Cancer Research, London, UK., Price A; Division of Molecular Pathology, The Institute of Cancer Research, London, UK., Jenner MW; Department of Haematology, University Hospital Southampton NHS Foundation Trust, Southampton, UK., Drayson MT; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK., Owen RG; Haematological Malignancy Diagnostic Service, St. James's University Hospital, Leeds, UK., Chown S; Gloucestershire Hospitals NHS Foundation Trust, Gloucester, UK., Lindsay J; Kent and Canterbury Hospital, Canterbury, UK., Karunanithi K; University Hospital of North Midlands, Stoke-on-Trent, UK., Hunter H; Derriford Hospital, Plymouth, UK., Gregory WM; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, Leeds, UK., Davies FE; Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA., Morgan GJ; Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA., Cook G; Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK., Atanesyan L; MRC-Holland, Amsterdam, The Netherlands., Savola S; MRC-Holland, Amsterdam, The Netherlands., Cairns DA; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, Leeds, UK., Jackson G; Department of Haematology, University of Newcastle, Newcastle Upon Tyne, UK., Houlston RS; Division of Molecular Pathology, The Institute of Cancer Research, London, UK.; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK., Kaiser MF; Division of Molecular Pathology, The Institute of Cancer Research, London, UK. Martin.Kaiser@icr.ac.uk.; Department of Hematology, The Royal Marsden Hospital, London, UK. Martin.Kaiser@icr.ac.uk.
Publikováno v:
Leukemia [Leukemia] 2021 Jul; Vol. 35 (7), pp. 2043-2053. Date of Electronic Publication: 2020 Dec 01.
Autor:
Jackson, GH, Davies, FE, Pawlyn, C, Cairns, DA, Striha, A, Collett, C, Hockaday, A, Jones, JR, Kishore, B, Garg, M, Williams, CD, Karunanithi, K, Lindsay, J, Jenner, MW, Cook, G, Russell, NH, Kaiser, MF, Drayson, MT, Owen, RG, Gregory, WM, Morgan, GJ, UK NCRI Haemato-oncology Clinical Studies Group
BACKGROUND: Patients with multiple myeloma treated with lenalidomide maintenance therapy have improved progression-free survival, primarily following autologous stem-cell transplantation. A beneficial effect of lenalidomide maintenance therapy on ove
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::5ba626b460de311f4bf4538fcef58dba
https://eprints.whiterose.ac.uk/140642/1/1-s2.0-S1470204518306879-main.pdf
https://eprints.whiterose.ac.uk/140642/1/1-s2.0-S1470204518306879-main.pdf
Autor:
Shah, V, Johnson, DC, Sherborne, AL, Ellis, S, Aldridge, FM, Howard-Reeves, J, Begum, F, Price, A, Kendall, J, Chiecchio, L, Savola, S, Jenner, MW, Drayson, MT, Owen, RG, Gregory, WM, Morgan, GJ, Davies, FE, Houlston, RS, Cook, G, Cairns, DA, Jackson, G, Kaiser, MF
Multiple myeloma (MM) is a genetically heterogeneous cancer of bone marrow plasma cells with variable outcome. To assess the prognostic relevance of clonal heterogeneity of TP53 copy number, we profiled tumors from 1777 newly diagnosed Myeloma XI tri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::cdeb30b742c6612e95008b7ecaeb7e15
https://europepmc.org/articles/PMC6533595/
https://europepmc.org/articles/PMC6533595/
Autor:
Shah, V, Sherborne, AL, Walker, BA, Johnson, DC, Boyle, EM, Ellis, S, Begum, DB, Proszek, PZ, Jones, JR, Pawlyn, C, Savola, S, Jenner, MW, Drayson, MT, Owen, RG, Houlston, RS, Cairns, DA, Gregory, WM, Cook, G, Davies, F, Jackson, GH, Morgan, GJ, Kaiser, MF
Robust establishment of survival in multiple myeloma (MM) and its relationship to recurrent genetic aberrations is required as outcomes are variable despite apparent similar staging. We assayed copy number alterations (CNA) and translocations in 1036
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::85ee3ae844525eae55a5c49d73e065df
https://eprints.whiterose.ac.uk/117302/16/leu2017179a.pdf
https://eprints.whiterose.ac.uk/117302/16/leu2017179a.pdf
Autor:
Jackson GH; Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK., Davies FE; Perlmutter Cancer Center, NYU Langone Health, New York, USA., Pawlyn C; The Institute of Cancer Research and The Royal Marsden Hospital NHS Foundation Trust, London, UK., Cairns DA; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, UK., Striha A; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, UK., Collett C; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, UK., Waterhouse A; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, UK., Jones JR; Kings College Hospital NHS Foundation Trust, London, UK., Kishore B; Heart of England NHS Foundation Trust, Birmingham, UK., Garg M; Leicester Royal Infirmary, Leicester, UK., Williams CD; Centre for Clinical Haematology, Nottingham University Hospital, Nottingham, UK., Karunanithi K; University Hospital of North Midlands, Stoke-on-Trent, UK., Lindsay J; East Kent Hospitals University NHS Foundation Trust, Canterbury, UK., Allotey D; Derby Teaching Hospitals NHS Foundation Trust, Derby, UK., Shafeek S; Worcestershire Acute Hospitals NHS Trust, Worcester, UK., Jenner MW; University Hospital Southampton NHS Foundation Trust, Southampton, UK., Cook G; Section of Experimental Haematology, Leeds Institute of Cancer and Pathology, University of Leeds, UK., Russell NH; Centre for Clinical Haematology, Nottingham University Hospital, Nottingham, UK., Kaiser MF; The Institute of Cancer Research and The Royal Marsden Hospital NHS Foundation Trust, London, UK., Drayson MT; Clinical Immunology, School of Immunity and Infection, University of Birmingham, UK., Owen RG; St James's University Hospital, Haematological Malignancy Diagnostic Service (HMDS), Leeds, UK., Gregory WM; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, UK., Morgan GJ; Perlmutter Cancer Center, NYU Langone Health, New York, USA., Clinical Studies Group UNHO
Publikováno v:
Haematologica [Haematologica] 2021 Jul 01; Vol. 106 (7), pp. 1957-1967. Date of Electronic Publication: 2021 Jul 01.